If you are not happy with the results below please do another search
While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved […]
This report, Kalorama’s Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity in cell and gene therapy. The report includes specific details of 1000+ deals from 2022-2023. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama’s CGT deals amounted to a […]
The Market for Single Cell Analysis in Genomics: Next-Generation Sequencing and Other Technology, 2023-2027 focuses on the market for single cell genomics products. Analyzed are the hardware, service of the hardware, software, and consumables included for the sequencing step and other types of downstream analysis. Single cell RNA-seq enables new types of analyses, for instance: […]
The concepts of cell therapy and gene therapy have been investigated for decades, but there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved […]
Cell and gene therapy is attracting much attention these days and for good reason. For one, there has been a notable increase in the number of cell and gene therapies in clinical development over the past decade. In the United States alone there are over 1,000 cell and gene therapies in clinical development, and more […]
With the 2022 Cell & Gene Meeting on the Mesa (#CGMesa22) underway, here’s a look at some notable recent developments in cell and gene therapy featured in the bimonthly newsletter, Cell and Gene Therapy Business Outlook. Myrtelle, a clinical-stage gene therapy company based in Wakefield, MA, and Forge Biologics, a gene therapy contract development and […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]
Email Us: Customer Service
Phone (US): 703-778-3080
Fax: 703-778-3081
